UC risk stratification optimised for patients presenting with microhaematuria.
Cxbladder Triage is an established test optimised for the risk stratification and rule of out of urothelial cancer (UC) in patients presenting with microhaematuria. Triage helps to de-intensify clinical work-up in those with a low probability Triage test result, reducing the need for referral and invasive procedures, while prioritising those who require further investigation.
Triage is included in the American Urological Association Microhaematuria Guideline¹, supported with "Grade A" evidence from the STRATA randomised controlled trial².
¹ Barocas et al. (2025) Updates to Microhematuria: AUA/SUFU Guideline (2025). The Journal of urology, 213(5), 547–557. https://doi.org/10.1097/JU.0000000000004490.
² Lotan et al. (2024) A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. The Journal of Urology Vol 212(1) 41-51.
• Analyses gene expression alongside information on known risk factors like age, gender and smoking history to help rule out urothelial cancer in those with a low risk of disease.
• Safely de-intensifies clinical workup in patients with a low probability Triage test result, while prioritising those who require immediate care.
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | 95% | |
| NPV | 99% |
Urine in Cxbladder container
30–50 mL midstream urine collected into the Cxbladder collection tube (contains preservative). Do not use catheter samples.
Available through Codex Genetics as the authorised Pacific Edge distributor in Hong Kong. Please contact us for test kits, collection instructions, and ordering.
Cxbladder specimens must be collected using the dedicated Cxbladder collection kit.
Please contact us for pricing.

The Cxbladder Triage score ranges from 0.0 to 10.0. Using a cut-off of 4.0, it identifies patients who have a low probability of having UC.